ArticleBJC reports2026
Mucosal melanoma in 1481 patients in the Netherlands. An overview of metastatic patterns, main driver mutations and the efficacy of therapeutic strategies.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal melanomas are a rare melanoma subtype with poor prognosis. This project aimed to identify the main driver mutations of the different mucosal melanomas and to evaluate the efficacy of targeted/immunotherapies in patients with metastatic disease in current practice. In addition, the baseline clinicopathological characteristics, metastatic patterns, and primary treatment strategies and survival of mucosal melanoma subtypes were studied.
methodsThe Dutch nationwide pathology databank (Palga) and the Netherlands Comprehensive Cancer Organisation (IKNL) were queried for all patients with a diagnosis of mucosal melanoma (1989-2021).
resultsThe dataset included a total of 1481 patients. Mutation status was assessed in 397 patients and in 170 patients (43%) a driver mutation was discovered. Patients with metastatic disease who received targeted/immunotherapy did show a better survival. The liver and lung were the predominant locations of the first metastasis.
conclusionsThe data in the present study implies that patients with metastatic disease mucosal melanoma might benefit from targeted/immunotherapies. Molecular analysis should be considered in these patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.